Primary care costs due to prodromal Alzheimer disease: a real-world study in patients with a 10-year or longer medical history

Abstract

Background

The aim of this study was to estimate primary care costs of prodromal signs/symptoms of Alzheimer disease (AD), during a 10-year or longer period preceding AD diagnosis, in relation to costs cumulated in the general population for the same reasons.

Methods

Nested case-control study involving 1889 AD cases and 18,890 controls aged 60+ from the Italian primary care Health Search Database (HSD). AD incident cases were through the International Classification of Diseases, 9th edition. Costs related to drugs, diagnostic tests and specialist referrals triggered by prodromal AD signs and/or symptoms were quantified and compared with costs cumulated by non-AD counterparts.

Results

During the pre-diagnosis 10-year or longer period, prodromal signs and symptoms trigger diagnostic and therapeutic costs 55% higher than those cumulated in general population for the same clinical reasons. After accounting for patients’ comorbidity and regional differences, the mean cost related to diagnostic and therapeutic procedures, and those related to specialist referrals, amounted to 854.1 €(SD: 630.6 €) in AD incident cases vs. 527.3 €(SD: 446.2) cumulated in patients not developing AD.

Conclusion

Prodromal AD manifestations are associated with primary care costs that resulted higher than those cumulated in the general population aged 60+. It remains to be elucidated if earlier dementia diagnoses would be associated with reduced costs triggered by the same clinical signs and symptoms.

Keywords:

• Costs
• Alzheimer’s disease
• dementia
• primary care

Transparency

Declaration of funding

This study was funded by Roche S.p.A.

Declaration of financial/other relationships

Valeria Lovato, is employed of Roche S.p.A., Monza, Italy. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgements

None.